Intestinal Microbiota Predicts Lung Cancer Patients at Risk of Immune-Related Diarrhea

Liu, Tian; Xiong, Qi; Hu, Yi

doi:10.2217/imt-2018-0144

Cited by 44 publications

(36 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gut microbiota variation is correlated with the risk of immune-related diarrhea in lung cancer patients after the treatment of anti-programed cell death protein-1 (anti-PD-1) antibodies. Phascolarctobacterium, as well as Bacteroides and Parabacteroides were more abundant whereas Veillonella was lower in patients without diarrhea (Liu T. et al, 2019). Given the vital role of gut microbiota in shaping immune responses, the influence of antibiotics on the efficacy of immunotherapy in patients with lung cancer was studied by a retrospective analysis.…”

Section: Lung Cancermentioning

confidence: 99%

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

et al. 2020

View full text Add to dashboard Cite

Emerging findings indicate there is a vital cross-talk between gut microbiota and the lungs, which is known as gut-lung axis. The gut disturbances in lung diseases including allergy, asthma, chronic obstructive pulmonary disease, cystic fibrosis and lung cancer were observed by extensive studies. Investigating how gut microbiota impact other distant organs is of great interest in recent years. Although it has not been fully understood whether the disturbance is the cause or effect of lung diseases, alterations in the gut microbial species and metabolites have been linked to changes in immune responses and inflammation as well as the disease development in the lungs. In this article, we systemically review the role and mechanisms underlying the changes in the constituent of gut microbiota and metabolites in lung diseases. In particular, the roles of gut-lung axis in mediating immune responses and reshaping inflammation are highlighted. Furthermore, we discuss the potential of strategies to manipulate the gut microbiota and metabolites as the therapeutic approach for lung diseases.

show abstract

Section: Lung Cancermentioning

confidence: 99%

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…(2018) observed that Alistipe s is one of the colon rectum cancer‐enriched genera. Diarrhea is the most common adverse immune‐related, and the increase in Phascolarctobacterium may aggravate this risk (Liu et al., 2019). The report also pointed a massive decrease in the genus of Phascolarctobacterium related to colonic inflammation (Bajer et al., 2017).…”

Section: Resultsmentioning

confidence: 99%

Gut microbiota regulation and anti‐inflammatory effect of β‐carotene in dextran sulfate sodium‐stimulated ulcerative colitis in rats

Zhu

Song

Liu

et al. 2021

Journal of Food Science

View full text Add to dashboard Cite

β-Carotene displays antioxidant and anti-inflammatory activities and prevents the development of cancer. Ulcerative colitis (UC) is a kind of inflammatory bowel disease that is accompanied by a certain risk of colon cancer. However, the role of β-carotene in the modulation of gut microbiota and UC improvement is unclear. In this research, the properties of β-carotene on anti-inflammatory and the composition of gut microbiota were evaluated in a rat model of UC induced by dextran sulfate sodium (DSS). The results revealed that β-carotene significantly (p < 0.05) decreased the severity of colitis in rats, as assessed using body weight (6.00 ± 1.73%), colon length (22.23 ± 0.53%), and disease activity index, and improved the structure of the colon damaged. Moreover, colonic levels of proinflammatory cytokines were significantly lower following β-carotene supplementation. β-Carotene intervention also lowered the expression levels of phosphorylated p65 (0.60 ± 0.02), p38 (0.57 ± 0.00), Erk (0.63 ± 0.04), and JNK (0.70 ± 0.00). The result of the relative abundance of gut microbiota showed that DSS administration significantly changed the microbial structure at the phylum and genus levels of rats. Furthermore, β-carotene treatment significantly increased the abundance of Faecalibacterium, the levels of which negatively correlated with the levels of inflammatory cytokines. Faecalibacterium may be a potential target in the alleviation of DSS-induced UC. β-Carotene can alleviate DSS-induced UC through the regulation of gut microbiota. This study provides a reference for the rational use of β-carotene in the treatment of UC.Practical Application: β-Carotene can relieve ulcerative colitis and regulate the gut microbiota; the nutritional intervention of β-carotene enhancing animal health.

show abstract

“…Data shows that gut microbiota has a strong influence on the efficacy of cancer immunotherapy, chemotherapy, and radiotherapy [ 77 ]. Monoclonal antibodies, such as anti-PD-1/PD-L1 or anti-CTLA-4, are successfully used in cancer immunotherapy [ 24 , 31 , 78 , 79 ]. There are many reports stating that microbiome has a significant role in enhancing or reducing the efficacy of immunotherapy [ 80 ] and disturbance of the physiological gut microbiome may lead to primary resistance to immune checkpoint therapy [ 32 , 80 , 81 ].…”

Section: The Impact Of Microbiome On the Efficacy Of The Immunotherapymentioning

confidence: 99%

“…Data shows that Bacteroides , Parabacteroides , and Firmicutes were more abundant in the gut of patients without diarrhea. Veillonella was less abundant in this kind of patients [ 79 ].…”

Section: The Impact Of Microbiome On the Efficacy Of The Immunotherapymentioning

confidence: 99%

Diet, Microbiome, and Cancer Immunotherapy—A Comprehensive Review

et al. 2021

View full text Add to dashboard Cite

The immune system plays a key role in cancer suppression. Immunotherapy is widely used as a treatment method in patients with various types of cancer. Immune checkpoint blockade using antibodies, such as anti-PD-1, anti-PD-L1, and anti-CTLA-4, is currently gaining popularity. A systematic literature search was executed, and all available data was summarized. This review shows that specific dietary patterns (such as, e.g., animal-based, vegetarian, or Mediterranean diet) alter the gut microbiome’s composition. An appropriate intestinal microbiota structure might modulate the function of human immune system, which affects the bodily anti-cancer response. This paper shows also that specific bacteria species inhabiting the gastrointestinal tract can have a beneficial influence on the efficacy of immunotherapy. Antibiotics weaken gut bacteria and worsen the immune checkpoint blockers’ efficacy, whereas a faecal microbiota transplant or probiotics supplementation may help restore bacterial balance in the intestine. Other factors (like vitamins, glucose, or BMI) change the cancer treatment response, as well. This review demonstrates that there is a strong association between one’s diet, gut microbiome composition, and the outcome of immunotherapy. However, further investigation on this subject is required.

show abstract

Intestinal Microbiota Predicts Lung Cancer Patients at Risk of Immune-Related Diarrhea

Cited by 44 publications

References 40 publications

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

Gut microbiota regulation and anti‐inflammatory effect of β‐carotene in dextran sulfate sodium‐stimulated ulcerative colitis in rats

Diet, Microbiome, and Cancer Immunotherapy—A Comprehensive Review

Contact Info

Product

Resources

About